OncoZenge Strengthens Phase 3 Sponsor Team for Regulatory Affairs
OncoZenge AB (publ) ("OncoZenge" or "the Company") today announces the reinforcement of its Phase 3 sponsor team for BupiZenge™ to manage regulatory affairs.
OncoZenge is pleased to announce that Christina Junvik is joining the Company through an expanded collaboration with PharmaRelations to enhance the Company’s preparedness for the Phase 3 project with BupiZenge™.
Christina will be responsible for the planning and coordination of regulatory activities and relevant documentation for interactions with authorities. She will also join the sponsor oversight team for the Company’s Phase 3 study, led by Anna Asplind, where she will play a key role in both operational and strategic decisions as well as in dialogue with CDMO, CRO, and commercial partners.
Christina Junvik brings over 20 years of experience in the pharmaceutical industry, with a focus on early clinical development, including clinical and regulatory strategy. She has held international roles at major pharmaceutical companies, such as Novartis Oncology, as well as positions in biotech, CRO, and as an independent consultant. She has also served as Head of Development at several biotechs.
BupiZenge™ – Potential to be the leading treatment for oral pain.
For additional information, please contact:
Stian Kildal, CEO, mobile: +46 76 115 3797, e-mail: stian.kildal@oncozenge.se
Certified Adviser
OncoZenge’s Certified Adviser is Redeye AB.
OncoZenge AB
Gustavslundsvägen 34, 167 51 Stockholm, Sweden
About this release
The information in this release was submitted for publication, through the agency of the contact persons set out above, at 10:00 CEST on April 4, 2025.
About OncoZenge
OncoZenge is dedicated to developing an innovative, effective, and well-tolerated treatment for oral pain in conditions where current options fall short, often due to insufficient pain relief or significant side effects. BupiZenge™ is a novel oral lozenge formulation of bupivacaine, a local anesthetic with decades of clinical experience. The lead indication for BupiZenge™ is oral pain caused by oral mucositis, an inflammatory condition affecting millions of cancer patients. Oral mucositis leads to severe physical and psychological distress, representing a significant unmet medical need for an effective, opioid-sparing treatment. In Phase 2 trials, BupiZenge™ demonstrated substantially better pain relief compared to the standard of care.
OncoZenge is headquartered in Stockholm, Sweden, and is publicly traded on Nasdaq First North Growth Market under the ticker ONCOZ.
